Inadequate Hospital Practices to Prevent Mother-to-Child Transmission of Hepatitis B Virus Infection: A European Survey.
Infant
Female
Infant, Newborn
Pregnancy
Humans
Hepatitis B virus
Hepatitis B Surface Antigens
Infectious Disease Transmission, Vertical
/ prevention & control
DNA, Viral
/ therapeutic use
Hepatitis B e Antigens
Hepatitis B
/ diagnosis
Hepatitis B Vaccines
Pregnancy Complications, Infectious
/ diagnosis
Journal
Journal of pediatric gastroenterology and nutrition
ISSN: 1536-4801
Titre abrégé: J Pediatr Gastroenterol Nutr
Pays: United States
ID NLM: 8211545
Informations de publication
Date de publication:
01 06 2023
01 06 2023
Historique:
medline:
22
5
2023
pubmed:
18
3
2023
entrez:
17
3
2023
Statut:
ppublish
Résumé
Prevention of vertical transmission of hepatitis B virus (HBV) infection is crucial to eliminate viral hepatitis as a major public health threat by 2030. We aimed to assess the current hospital policies and practices implemented before, at, and after birth, and to evaluate potential barriers to the full application of international guidelines. A web-based survey was supported by PENTA Foundation and distributed across Europe from October to December 2021. Overall, 76 centers with delivery departments completed the survey. Hepatitis B surface antigen (HBsAg) maternal screening is performed in the first trimester of pregnancy in 53% of the centers and in the third in 46%. HBsAg positive pregnant women are tested for serologic HBV markers and HBV-DNA in 78% and 63% of the departments; 38% of the HBeAg positive women with high HBV-DNA levels are treated during the last trimester of pregnancy. At birth, 91% of the departments administer HBV vaccine to infants born to HBsAg positive mothers within 12 hours of birth; 74% test women with unknown HBsAg status and 78% of them wait for the maternal testing results before administering HBV vaccine to their newborns. After birth, 47% of the departments provide postvaccination serological testing for infants born to HBsAg positive mothers. The timing of the HBV vaccine schedule varies greatly. There is significant heterogeneity in the hospital policies and correlated procedures. The implementation of a multidisciplinary clinical pathway is a must if a stronger connection between the prenatal, perinatal, and postnatal phases is to be established.
Identifiants
pubmed: 36930981
doi: 10.1097/MPG.0000000000003765
pii: 00005176-202306000-00006
doi:
Substances chimiques
Hepatitis B Surface Antigens
0
DNA, Viral
0
Hepatitis B e Antigens
0
Hepatitis B Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
716-722Informations de copyright
Copyright © 2023 by European Society for European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Koneru A, Fenlon N, Schillie S, Williams C, Weng MK, Nelson N. National perinatal hepatitis B prevention program: 2009–2017. Pediatrics. 2021;147:e20201823.
Cheung KW, Seto MTY, Lao TT. Prevention of perinatal hepatitis B virus transmission. Arch Gynecol Obstet. 2019;300:251–9.
World Health Organization. Global Health Sector Strategy on Viral Hepatitis 2016–2021. Global Hepatitis Programme Department of HIV/AIDS. Geneva: World Health Organization; 2016.
World Health Organization. Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections, 2021. Accountability for the Global Health Sector Strategies 2016–2021: Actions for Impact. Geneva: World Health Organization; 2021.
Waheed Y. Progress on global hepatitis elimination targets. World J Gastroenterol. 2021;27:8199–200.
Indolfi G, Easterbrook P, Dusheiko G, et al. Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019;4:466–76 [published correction appears in Lancet Gastroenterol Hepatol . 2020 May;5(5):e4].
Tosun S, Aygün O, Özdemir HO, Korkmaz E, Özdemir D. The impact of economic and social factors on the prevalence of hepatitis B in Turkey. BMC Public Health. 2018;18:649.
Liu CJ, Kao JH. Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J. Semin Liver Dis. 2013;33:97–102.
World Health Organization. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. Geneva: World Health Organization; 2015 (Issue April).
European Centre for Disease Prevention and Control (ECDC). Hepatitis B: Annual Epidemiological Report for 2019: ECDC. 2019. Available at: https://www.ecdc.europa.eu/sites/default/files/documents/AER-Hepatitis-B-2019.pdf . accessed: 27 June 2022.
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–99.
Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH; American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261–83.
World Health Organization. Prevention of Mother-to-Child Transmission of Hepatitis B Virus: Guidelines on Antiviral Prophylaxis in Pregnancy. Geneva: World Health Organization; 2020. Available at: https://apps.who.int/iris/bitstream/handle/10665/333391/9789240002708-eng.pdf?sequence=1&isAllowed=y , accessed: 27 March 2023.
Brown RS Jr, McMahon BJ, Lok AS, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis. Hepatology. 2016;63:319–33.
Global Hepatitis Report 2017. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO. Available at: https://www.who.int/publications/i/item/9789241565455 , accessed: 27 March 2023.
World Health Organization. Immunization, Vaccines and Biologicals. Viral Hepatitis Policy and Practice: Report of a Survey of WHO Member States. 2010. World Health Organization; 2013. Available at: https://apps.who.int/iris/bitstream/handle/10665/85397/9789241564632_eng.pdf . accessed: 27 March 2023.
Beasley RP. Rocks along the road to the control of HBV and HCC. Ann Epidemiol. 2009;19:231–4.
Harder KM, Cowan S, Eriksen MB, Krarup HB, Christensen PB. Universal screening for hepatitis B among pregnant women led to 96% vaccination coverage among newborns of HBsAg positive mothers in Denmark. Vaccine. 2011;29:9303–7.
Willis BC, Wortley P, Wang SA, Jacques-Carroll L, Zhang F. Gaps in hospital policies and practices to prevent perinatal transmission of hepatitis B virus. Pediatrics. 2010;125:704–11.
Pinon M, Giugliano L, Nicastro E, et al. Timely birth dose vaccine to prevent vertical transmission of hepatitis B: a single center experience on the road to the WHO elimination goals in Italy. Vaccines (Basel). 2021;9:801.
Prabhu M, Susich MK, Packer CH, Hersh AR, Riley LE, Caughey AB. Universal hepatitis B antibody screening and vaccination in pregnancy: a cost-effectiveness analysis. Obstet Gynecol. 2022;139:357–67. doi:10.1097/AOG.0000000000004652. Erratum in: Obstet Gynecol. 2022 Apr 1;139(4):696.
doi: 10.1097/AOG.0000000000004652.
Henderson JT, Webber EM, Bean SI. Screening for Hepatitis B Virus Infection in Pregnant Women: An Updated Systematic Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2019.
Jourdain G, Ngo-Giang-Huong N, Harrison L, et al. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. N Engl J Med. 2018;378:911–23.
Kushner T, Kaplowitz E, Mei R, et al. Adherence to pregnancy hepatitis B care guidelines in women and infants in the United States and evaluation of two interventions to improve care: a multicentre hospital-based study. J Viral Hepat. 2021;28:582–91. doi:10.1111/jvh.13459.
doi: 10.1111/jvh.13459
Calvo PL, Pinon M, Dell’Olio D, et al. Management of hepatitis-B virus infection in immunocompromised children: a single center experience. J Pediatr Gastroenterol Nutr. 2021;72:597–602.
Indolfi G, Abdel-Hady M, Bansal S, et al. Management of hepatitis B virus infection and prevention of hepatitis B virus reactivation in children with acquired immunodeficiencies or undergoing immune suppressive, cytotoxic, or biological modifier therapies. J Pediatr Gastroenterol Nutr. 2020;70:527–38.